Fever and Neutropenia (IDSA Bundle)

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, Enjoy!

Issue link:

Contents of this Issue


Page 15 of 15

Strength of Recommendation and Quality of Evidence Category/Grade Definition Strength of Recommendation A Good evidence to support a recommendation for or against use. B Moderate evidence to support a recommendation for or against use. C Poor evidence to support a recommendation. Quality of Evidence I Evidence from ≥ 1 properly randomized, controlled trial. II Evidence from ≥ 1 well-designed clinical trial, without randomization; from cohort or case-controlled analytic studies (preferably from > 1 center); from multiple time-series; or from dramatic results of uncontrolled experiments. III Evidence from opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees. Abbreviations AML/MDS, acute myeloid leukemia/myelodysplastic syndrome; ANC, absolute neutrophil count; CLABSI, central line-associated blood stream infections; CSF, colonystimulating factor; ESBL, extended-spectrum beta-lactamase; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HEPA, high-efficiency particulate air; HSCT, hematopoietic stem cell transplantation; HSV, herpes simplex virus; KPC, Klebsiella pneumoniae carbapenemase; MASCC, Multinational Association for Supportive Care in Cancer; MRSA, methicillin-resistant Staphylococcus aureus; RSV, respiratory syncytial virus; VRE, vancomycin-resistant enterococcus; VZV, varicella-zoster virus Source Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-e93. Disclaimer This Guideline attempts to define principles of practice that should produce high-quality patient care. It is applicable to specialists, primary care, and providers at all levels. This Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. The ultimate judgment concerning the propriety of any course of conduct must be made by the clinician after consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. 5740 Executive Drive  Suite 218 Baltimore, MD 21228  TEL: 410-869-3332  •  FAX: 410-744-2150  For additional copies: Copyright © 2011 All rights reserved FEV081112

Articles in this issue

Links on this page

Archives of this issue

view archives of IDSA GUIDELINES Bundle - Fever and Neutropenia (IDSA Bundle)